San Diego, CA, United States of America

Lalit Raj Peddakota

USPTO Granted Patents = 1 


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lalit Raj Peddakota: Innovator in Autism Treatment

Introduction

Lalit Raj Peddakota is a notable inventor based in San Diego, CA. He has made significant contributions to the field of autism treatment through his innovative research and patent work. His dedication to improving the lives of individuals with autism spectrum disorders is evident in his groundbreaking inventions.

Latest Patents

Lalit Raj Peddakota holds a patent for "Intranasal carbetocin formulations and methods for the treatment of autism." This patent focuses on methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, aimed at preventing and treating autism spectrum disorders. The methods and compositions are effective in addressing various symptoms, including social withdrawal, eye contact avoidance, and anxiety. His work also explores the use of oxytocin in combination with other therapeutic agents to enhance treatment efficacy.

Career Highlights

Lalit Raj Peddakota is currently associated with Retrophin, Inc., where he continues to advance his research in the field of autism treatment. His innovative approach and commitment to addressing the challenges faced by individuals with autism have positioned him as a key figure in this area of study.

Collaborations

Some of his coworkers include Alexis Kays Leonard and Joshua Sestak, who contribute to the collaborative efforts in research and development at Retrophin, Inc.

Conclusion

Lalit Raj Peddakota's work in developing intranasal carbetocin formulations represents a significant advancement in the treatment of autism spectrum disorders. His innovative contributions continue to inspire progress in the field, ultimately aiming to improve the quality of life for those affected by these conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…